Compounds > kl001
Page last updated: 2024-12-10

kl001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KL001: inhibits degradation of the cryptochrome; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2888648
CHEMBL ID1498001
SCHEMBL ID15380452
MeSH IDM0576942

Synonyms (54)

Synonym
CBMICRO_005790
IDI1_002505
OPREA1_152161
BIM-0006034.P001
kl 001
OPREA1_419357
CHEMDIV2_003790
EU-0005302
MLS000110334 ,
smr000106264
n-[3-(9h-carbazol-9-yl)-2-hydroxypropyl]-n-(furan-2-ylmethyl)methanesulfonamide
STK839587
HMS1379M06
AKOS000581142
MLS002540427
NCGC00079434-02
n-(3-carbazol-9-yl-2-hydroxypropyl)-n-(furan-2-ylmethyl)methanesulfonamide
HMS2371E17
CB08282
smsf0015860
F1345-0456
309928-48-1
n-(3-(9h-carbazol-9-yl)-2-hydroxypropyl)-n-(furan-2-ylmethyl)methanesulfonamide ,
NCGC00079434-03
doi:10.14272/oqafdlpapssohy-uhfffaoysa-n
10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N
S6304
CHEMBL1498001
AKOS016386481
OQAFDLPAPSSOHY-UHFFFAOYSA-N ,
MLS006011739
n-[3-(9h-carbazol-9-yl)-2-hydroxypropyl]-n-(2-furanylmethyl)methanesulfonamide
SCHEMBL15380452
n-(3-carbazol-9-yl-2-hydroxy-propyl)-n-(2-furfuryl)methanesulfonamide
bdbm56256
cid_2888648
n-(3-carbazol-9-yl-2-oxidanyl-propyl)-n-(furan-2-ylmethyl)methanesulfonamide
n-[3-(9-carbazolyl)-2-hydroxypropyl]-n-(2-furanylmethyl)methanesulfonamide
SR-01000436091-1
sr-01000436091
EX-A5290
NCGC00079434-06
kl001
BRD-A94580299-001-08-8
kl001(kl-001;kl 001)
n-[3-(9h-carbazol-9-yl)-2-hydroxypropyl]-n-[(furan-2-yl)methyl]methanesulfonamide
A911443
MS-26739
AC-36771
HY-108468
E80499
CS-0028859
EN300-115714
Z56824134

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with KL001 (a CRY1/2 activator) reduces excessive and "relapse" alcohol drinking in mice. "( Blockade of alcohol excessive and "relapse" drinking in male mice by pharmacological cryptochrome (CRY) activation.
Kreek, MJ; Zhou, Y, 2021)		0.96

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency39.81070.631035.7641100.0000AID504339
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
glp-1 receptor, partialHomo sapiens (human)Potency1.99530.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.95260.100020.879379.4328AID588453
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926
EWS/FLI fusion proteinHomo sapiens (human)Potency23.87560.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency19.95260.28189.721235.4813AID2326
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency3.26430.00419.984825.9290AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency95.28340.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency14.12540.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency10.00000.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
kallikrein-5 preproproteinHomo sapiens (human)IC50 (µMol)50.00001.359211.306050.0000AID1431
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Period circadian protein homolog 2Homo sapiens (human)EC50 (µMol)0.87000.87000.87000.8700AID1272827; AID1370816
Cryptochrome-1Homo sapiens (human)EC50 (µMol)4.87500.34004.87509.4100AID1411247; AID1411248
Cryptochrome-2Homo sapiens (human)EC50 (µMol)0.60500.34000.60500.8700AID1370816; AID1411247
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIPeriod circadian protein homolog 2Homo sapiens (human)
response to ischemiaPeriod circadian protein homolog 2Homo sapiens (human)
glycogen biosynthetic processPeriod circadian protein homolog 2Homo sapiens (human)
gluconeogenesisPeriod circadian protein homolog 2Homo sapiens (human)
chromatin remodelingPeriod circadian protein homolog 2Homo sapiens (human)
fatty acid metabolic processPeriod circadian protein homolog 2Homo sapiens (human)
circadian rhythmPeriod circadian protein homolog 2Homo sapiens (human)
regulation of vasoconstrictionPeriod circadian protein homolog 2Homo sapiens (human)
lactate biosynthetic processPeriod circadian protein homolog 2Homo sapiens (human)
negative regulation of protein ubiquitinationPeriod circadian protein homolog 2Homo sapiens (human)
circadian regulation of gene expressionPeriod circadian protein homolog 2Homo sapiens (human)
regulation of circadian rhythmPeriod circadian protein homolog 2Homo sapiens (human)
negative regulation of circadian rhythmPeriod circadian protein homolog 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionPeriod circadian protein homolog 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPeriod circadian protein homolog 2Homo sapiens (human)
regulation of neurogenesisPeriod circadian protein homolog 2Homo sapiens (human)
regulation of insulin secretionPeriod circadian protein homolog 2Homo sapiens (human)
white fat cell differentiationPeriod circadian protein homolog 2Homo sapiens (human)
regulation of cell cyclePeriod circadian protein homolog 2Homo sapiens (human)
regulation of glutamate uptake involved in transmission of nerve impulsePeriod circadian protein homolog 2Homo sapiens (human)
negative regulation of fat cell proliferationPeriod circadian protein homolog 2Homo sapiens (human)
circadian regulation of translationPeriod circadian protein homolog 2Homo sapiens (human)
positive regulation of cold-induced thermogenesisPeriod circadian protein homolog 2Homo sapiens (human)
negative regulation of transcription regulatory region DNA bindingPeriod circadian protein homolog 2Homo sapiens (human)
entrainment of circadian clock by photoperiodPeriod circadian protein homolog 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICryptochrome-1Homo sapiens (human)
gluconeogenesisCryptochrome-1Homo sapiens (human)
circadian rhythmCryptochrome-1Homo sapiens (human)
response to light stimulusCryptochrome-1Homo sapiens (human)
blue light signaling pathwayCryptochrome-1Homo sapiens (human)
response to activityCryptochrome-1Homo sapiens (human)
lipid storageCryptochrome-1Homo sapiens (human)
negative regulation of protein ubiquitinationCryptochrome-1Homo sapiens (human)
positive regulation of protein ubiquitinationCryptochrome-1Homo sapiens (human)
response to insulinCryptochrome-1Homo sapiens (human)
circadian regulation of gene expressionCryptochrome-1Homo sapiens (human)
response to glucagonCryptochrome-1Homo sapiens (human)
glucose homeostasisCryptochrome-1Homo sapiens (human)
regulation of circadian rhythmCryptochrome-1Homo sapiens (human)
negative regulation of circadian rhythmCryptochrome-1Homo sapiens (human)
signal transduction in response to DNA damageCryptochrome-1Homo sapiens (human)
entrainment of circadian clock by photoperiodCryptochrome-1Homo sapiens (human)
negative regulation of gluconeogenesisCryptochrome-1Homo sapiens (human)
positive regulation of gluconeogenesisCryptochrome-1Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayCryptochrome-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionCryptochrome-1Homo sapiens (human)
regulation of DNA damage checkpointCryptochrome-1Homo sapiens (human)
negative regulation of glucocorticoid receptor signaling pathwayCryptochrome-1Homo sapiens (human)
negative regulation of glucocorticoid secretionCryptochrome-1Homo sapiens (human)
photoreactive repairCryptochrome-2Homo sapiens (human)
regulation of sodium-dependent phosphate transportCryptochrome-2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICryptochrome-2Homo sapiens (human)
protein import into nucleusCryptochrome-2Homo sapiens (human)
circadian rhythmCryptochrome-2Homo sapiens (human)
response to light stimulusCryptochrome-2Homo sapiens (human)
blue light signaling pathwayCryptochrome-2Homo sapiens (human)
response to activityCryptochrome-2Homo sapiens (human)
lipid storageCryptochrome-2Homo sapiens (human)
negative regulation of phosphoprotein phosphatase activityCryptochrome-2Homo sapiens (human)
response to insulinCryptochrome-2Homo sapiens (human)
circadian regulation of gene expressionCryptochrome-2Homo sapiens (human)
glucose homeostasisCryptochrome-2Homo sapiens (human)
regulation of circadian rhythmCryptochrome-2Homo sapiens (human)
negative regulation of circadian rhythmCryptochrome-2Homo sapiens (human)
entrainment of circadian clock by photoperiodCryptochrome-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionCryptochrome-2Homo sapiens (human)
negative regulation of glucocorticoid receptor signaling pathwayCryptochrome-2Homo sapiens (human)
negative regulation of glucocorticoid secretionCryptochrome-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPeriod circadian protein homolog 2Homo sapiens (human)
transcription coactivator activityPeriod circadian protein homolog 2Homo sapiens (human)
protein bindingPeriod circadian protein homolog 2Homo sapiens (human)
transcription corepressor bindingPeriod circadian protein homolog 2Homo sapiens (human)
deoxyribodipyrimidine photo-lyase activityCryptochrome-1Homo sapiens (human)
DNA (6-4) photolyase activityCryptochrome-1Homo sapiens (human)
double-stranded DNA bindingCryptochrome-1Homo sapiens (human)
protein bindingCryptochrome-1Homo sapiens (human)
blue light photoreceptor activityCryptochrome-1Homo sapiens (human)
nuclear receptor bindingCryptochrome-1Homo sapiens (human)
protein kinase bindingCryptochrome-1Homo sapiens (human)
phosphatase bindingCryptochrome-1Homo sapiens (human)
histone deacetylase bindingCryptochrome-1Homo sapiens (human)
E-box bindingCryptochrome-1Homo sapiens (human)
FAD bindingCryptochrome-1Homo sapiens (human)
DNA bindingCryptochrome-1Homo sapiens (human)
deoxyribodipyrimidine photo-lyase activityCryptochrome-2Homo sapiens (human)
DNA (6-4) photolyase activityCryptochrome-2Homo sapiens (human)
transcription cis-regulatory region bindingCryptochrome-2Homo sapiens (human)
DNA bindingCryptochrome-2Homo sapiens (human)
damaged DNA bindingCryptochrome-2Homo sapiens (human)
single-stranded DNA bindingCryptochrome-2Homo sapiens (human)
protein bindingCryptochrome-2Homo sapiens (human)
blue light photoreceptor activityCryptochrome-2Homo sapiens (human)
nuclear receptor bindingCryptochrome-2Homo sapiens (human)
protein kinase bindingCryptochrome-2Homo sapiens (human)
phosphatase bindingCryptochrome-2Homo sapiens (human)
FAD bindingCryptochrome-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleusPeriod circadian protein homolog 2Homo sapiens (human)
nucleoplasmPeriod circadian protein homolog 2Homo sapiens (human)
nucleolusPeriod circadian protein homolog 2Homo sapiens (human)
cytosolPeriod circadian protein homolog 2Homo sapiens (human)
perinuclear region of cytoplasmPeriod circadian protein homolog 2Homo sapiens (human)
Cry-Per complexPeriod circadian protein homolog 2Homo sapiens (human)
cytoplasmPeriod circadian protein homolog 2Homo sapiens (human)
nucleusPeriod circadian protein homolog 2Homo sapiens (human)
nucleusCryptochrome-1Homo sapiens (human)
mitochondrionCryptochrome-1Homo sapiens (human)
cytoplasmCryptochrome-1Homo sapiens (human)
nucleusCryptochrome-1Homo sapiens (human)
extracellular regionCryptochrome-2Homo sapiens (human)
nucleusCryptochrome-2Homo sapiens (human)
mitochondrionCryptochrome-2Homo sapiens (human)
cytosolCryptochrome-2Homo sapiens (human)
nuclear speckCryptochrome-2Homo sapiens (human)
Cry-Per complexCryptochrome-2Homo sapiens (human)
cytoplasmCryptochrome-2Homo sapiens (human)
nucleusCryptochrome-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1370816Modulation activity at CRY2/PER2 in human U2OS cells harboring per2-dLuc assessed as activation of per2 activity measured every 100 mins for 5 days by luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Carbazole-containing amides and ureas: Discovery of cryptochrome modulators as antihyperglycemic agents.
AID1272827Reduction of amplitude effect of PER2 in human U2OS cells harboring Per2-dLuc luciferase reporter gene assessed as effects on circadian rhythms2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Carbazole-containing sulfonamides and sulfamides: Discovery of cryptochrome modulators as antidiabetic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.17)29.6817
2010's13 (54.17)24.3611
2020's10 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.18 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index37.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.1106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		2.1110elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.1110L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		2.1110amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.2510mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
flavin-adenine dinucleotide
Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)		2.0810flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group
longdaysin
[no description available]		2.110
sr9009
[no description available]		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Alloxan Diabetes
[description not available]		02.5520
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.1710
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Astrocytoma, Grade IV
[description not available]		02.4110
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.4110
Recrudescence
[description not available]		02.3110
Alcohol Abuse
[description not available]		02.3110
Drug Withdrawal Symptoms
[description not available]		02.3110
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		02.3110
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		02.3110
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		02.3110